Digital health company Verana Health (San Francisco) has unveiled the Qdata anti-VEGF market tracker. It is their first market tracking Data as a Service (DaaS) product.
Excessive amounts of vascular endothelial growth factor (VEGF) can cause abnormal blood vessel growth in the eyes, which, when untreated, can result in vision loss in patients with retinal diseases. Consequently, anti-VEGF therapies help preserve eyesight for patients with conditions such as age-related macular degeneration and diabetic retinopathy.
Qdata anti-VEGF market tracker supports brand-level analysis
The Qdata anti-VEGF market tracker enables comprehensive brand-level analysis. It also provides direct access to real-world data, according to Sujay Jadhav, Verana Health’s CEO. The service offers accurate and timely insights into product performance and market dynamics.
Sujay Jadhav
Real-world data is drawn from the American Academy of Ophthalmology’s IRIS Registry (Intelligent Research in Sight). The market tracker is offered in AWS Data Exchange. This service enables Amazon Web Services (AWS) customers to use third-party data in the cloud.
The tracker is built on a secure cloud infrastructure. It has customizable market dashboards and features a highly intuitive visualization layer. This allows life sciences companies to customize data reporting and monitor market uptake.
The Qdata anti-VEGF market tracker enables users to access data that is roughly one-month old. Jadhav said, “Historically, people have used claims data as a source to understand anti-VEGF usage patterns.” That practice typically resulted in a two- to three-month delay in reviewing anti-VEGF medication use in a given month.
The tracker offers granular market segmentation at the brand level. This enables drug companies to analyze the performance of specific anti-VEGF products.
Comprehensive de-identified data
The Qdata anti-VEGF market tracker draws data from more than 850,000 patients and 4.8 million anti-VEGF injections. It provides “a comprehensive module of de-identified structured and unstructured electronic health record (EHR) data, curated securely and compliantly for insight delivery,” said Jadhav. With data from over 2,300 clinicians across six key indications, he emphasized the service’s wide-ranging data set. He stated that it “ensures reliable and accurate insights.”
Jadhav said the Qdata anti-VEGF market tracker can inform commercial planning and sales forecasting. It provides an overview of market share by drug. “The tracker supports longitudinal data and real-world evidence, which can inform commercial strategies for companies selling anti-VEGF agents,” according to Jadhav. It also offers information about medication switching. He added, “Life sciences companies can customize data reporting and monitor market uptake for products. They can adapt to the specific needs and goals in a highly competitive market.”
The IRIS Registry, launched in 2014, was the first comprehensive eye disease clinical registry in the U.S. It supports research, quality improvement, and patient care initiatives. The registry is a collaborative project between the American Academy of Ophthalmology and Verana Health. It is one of the largest specialty society clinical data registries in medicine. The IRIS Registry contains data from millions of patients and various clinical settings. This contributes to a better understanding of eye diseases and treatment outcomes. As of 2023, the registry includes data on 2.2 million patients who received anti-VEGF injections. This provides a robust dataset for the Qdata anti-VEGF market tracker. It enables granular analysis of the anti-VEGF market and its trends.
Filed Under: Drug Discovery and Development, Ophthalmology
